RPL24 as a potential prognostic biomarker for cervical cancer treated by Cisplatin and concurrent chemoradiotherapy

Cheng Ming; Xuelian Bai; Lifeng Zhao; Dedong Yu; Xiaomin Wang; Yun Wu

doi:10.3389/fonc.2023.1131803

RPL24 as a potential prognostic biomarker for cervical cancer treated by Cisplatin and concurrent chemoradiotherapy

Front Oncol. 2023 Oct 18:13:1131803. doi: 10.3389/fonc.2023.1131803. eCollection 2023.

Authors

Cheng Ming¹, Xuelian Bai², Lifeng Zhao², Dedong Yu², Xiaomin Wang³, Yun Wu²

Affiliations

¹ Department of Oncology, Baotou Central Hospital, Inner Mongolia Medical University, Baotou, China.
² Department of Oncology, Baotou Central Hospital, Baotou, China.
³ Institute of Translational Medicine, Baotou Central Hospital, Baotou, China.

Abstract

Cervical carcinoma (CC) is the one of most common gynecologic cancers worldwide. The ribosomal proteins (RPs) are essential for ribosome assembly and function, and it has been verified that the abnormal expression of RPs was closely associated with tumorigenesis. In this study, we found that the RP large subunit 24 (RPL24) expression level was upregulated after the CC cell lines SiHa and HeLa were treated with Cisplatin (CDDP) in vitro. Simultaneously, a nude mouse xenograft model was used to examine the effect of RPL24 on tumor growth in vivo, which showed that overexpression of RPL24 can suppress tumor growth. Furthermore, we proved that RPL24 expression increased after CC patients were treated with concurrent chemoradiotherapy (CCRT), and the higher expression of RPL24 predicted a better prognosis using clinical data from 40 CC patients, verified via the Kaplan-Meier Plotter and LOGpc. These results revealed that RPL24 can be considered a potential biomarker to predict the prognosis of CC patients and assess CCRT efficacy.

Keywords: RPL24; biomarker; cervical cancer; concurrent chemoradiotherapy; prognosis.

Grants and funding

The current study was supported by the National Natural Science Foundation of China (Nos. 81860447 and 82160518) and the Natural Science Foundation of Inner Mongolia (Nos. 2020MS08004, 2020MS08053, and 2021MS08051).